Literature DB >> 20137967

Clinical outcome of resected solid-type small-sized c-stage IA non-small cell lung cancer.

Masayoshi Inoue1, Masato Minami, Noriyoshi Sawabata, Tomoki Utsumi, Yoshihisa Kadota, Norihisa Shigemura, Meinoshin Okumura.   

Abstract

BACKGROUND: The chances of pulmonary resection for small-sized lung cancer have increased because of the development of thin-slice computed tomography (CT). Though sublobar resection could be indicated for ground glass opacity (GGO)-dominant adenocarcinoma with low-grade behaviour, the malignant potential of solid-type, small-sized lung cancer has not been sufficiently assessed. We aimed to address the clinical outcomes of resected solid-type c-stage IA non-small cell lung cancer (NSCLC) smaller than 2 cm.
METHODS: A retrospective observational study involving 118 patients who had undergone a complete resection for lung cancer smaller than 2 cm with solid component more than 50% on CT was conducted, and their postoperative survival and recurrence pattern were analysed.
RESULTS: Thirty-five patients with solid component-dominant lesion (SCDL) and 83 patients with pure solid lesion (PSL) without GGO were enrolled. Lymph node involvement was found in 15 patients with PSL (18%). The 5-year disease-free survival (DFS) was 100% in SDCL patients and 83% in PSL patients. Multivariate analysis of PSL patients showed that lymph node metastasis and pleural invasion were independent negative prognostic predictors. The 5-year DFS was 88%, 80% and 46% in p-N0, p-N1 and p-N2 patients, respectively. The 5-year DFS was 33% for patients with pleural invasion, which was significantly worse than that for patients without pleural involvement. Postoperative recurrence was mainly observed as intrathoracic lesions within 3 years.
CONCLUSIONS: A proportion of solid-type NSCLC has malignant potential, even for tumours smaller than 2 cm. Periodic intrathoracic evaluation is required following complete resection. Copyright 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20137967     DOI: 10.1016/j.ejcts.2009.12.030

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  13 in total

1.  The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients.

Authors:  Morgan L Cox; Chi-Fu Jeffrey Yang; Paul J Speicher; Kevin L Anderson; Zachary W Fitch; Lin Gu; Robert Patrick Davis; Xiaofei Wang; Thomas A D'Amico; Matthew G Hartwig; David H Harpole; Mark F Berry
Journal:  J Thorac Oncol       Date:  2017-01-08       Impact factor: 15.609

2.  Selective mediastinal lymphadenectomy without intraoperative frozen section examinations for clinical stage I non-small-cell lung cancer: retrospective study of 403 cases.

Authors:  Wei Jiang; Xiaoke Chen; Junjie Xi; Qun Wang
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

3.  Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer.

Authors:  Norifumi Tsubokawa; Yasuhiro Tsutani; Yoshihiro Miyata; Yoshinori Handa; Keizo Misumi; Hideaki Hanaki; Eisuke Hida; Morihito Okada
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

Review 4.  Controversies on lung cancers manifesting as part-solid nodules.

Authors:  Rowena Yip; Kunwei Li; Li Liu; Dongming Xu; Kathleen Tam; David F Yankelevitz; Emanuela Taioli; Betsy Becker; Claudia I Henschke
Journal:  Eur Radiol       Date:  2017-08-23       Impact factor: 5.315

5.  Surgical outcome of wide wedge resection in poor-risk patients with clinical-N0 non-small cell lung cancer.

Authors:  Hiroaki Tsunezuka; Daishiro Kato; Satoru Okada; Tatsuo Furuya; Junichi Shimada; Masayoshi Inoue
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-07-26

Review 6.  Recurrence after surgery in patients with NSCLC.

Authors:  Hidetaka Uramoto; Fumihiro Tanaka
Journal:  Transl Lung Cancer Res       Date:  2014-08

7.  Sublobar resection versus lobectomy in solid-type, clinical stage IA, non-small cell lung cancer.

Authors:  Hyun Woo Jeon; Young-Du Kim; Kyung Soo Kim; Sook Whan Sung; Hyung Joo Park; Jae Kil Park
Journal:  World J Surg Oncol       Date:  2014-07-16       Impact factor: 2.754

8.  Modified inflammation-based score as an independent malignant predictor in patients with pulmonary focal ground-glass opacity: a propensity score matching analysis.

Authors:  Long Jiang; Shanshan Jiang; Yongbin Lin; Han Yang; Zerui Zhao; Zehua Xie; Yaobin Lin; Hao Long
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

9.  Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid or solid-dominant stage IA non-small cell lung cancer.

Authors:  Sunyin Rao; Lianhua Ye; Li Min; Guangqiang Zhao; Ya Chen; Yunchao Huang; Jichen Yang; Shouyong Xiao; Run Cao
Journal:  J Cardiothorac Surg       Date:  2019-11-13       Impact factor: 1.637

10.  Less is more in solid-dominant lung cancer? Sublobar resection versus lobectomy for solid-dominant stage IA non-small-cell lung cancer: A meta-analysis study.

Authors:  Juntang Guo; Yang Liu; Xiaodong Tian; Zhipeng Ren; Jixing Lin; Bailin Wang; Chaoyang Liang
Journal:  Mol Clin Oncol       Date:  2019-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.